Physician

Romy Jove Cabacungan, M.D.

According to 2025 Medicare claims, Romy Cabacungan, M.D. (NPI: 1417190828) practices rheumatology in the Tucson, AZ market, with the plurality of this provider's patient population coming from Pima, AZ. This provider's primary affiliated billing organization is ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES P C (NPI: 1366489254; TIN: 860765242) and primary practice location at 85704-1141. Cabacungan is affiliated with the ABC Network (ACO ID: A5554), participating under the MSSP model.

Cabacungan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 593 traditional Medicare patients, billed 171,761 HCPCS/CPT codes, and received $1,738,762 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,043 prescription claims across 516 beneficiaries totaling $3,937,217 in drug costs, led by Humira(Cf) Pen (Adalimumab). 2015 DME data shows 15 claims. Open Payments data shows 186 records totaling $121,599. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $18,917 to $1,738,762. Similarly, Part D prescription costs have moved sharply higher in recent years, from $11,508 to $3,937,217. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	107	280	$18,917
2016	N/R	N/R	N/R
2017	48	289	$16,374
2018	264	13,725	$365,195
2019	374	29,254	$690,479
2020	447	46,607	$974,344
2021	446	86,156	$1,317,581
2022	459	115,652	$1,360,627
2023	513	132,864	$1,495,796
2024	593	171,761	$1,738,762

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	60	123	$11,508
2016	146	660	$232,757
2017	153	582	$295,530
2018	224	1,132	$267,356
2019	260	1,537	$743,901
2020	314	1,534	$794,242
2021	290	1,195	$860,245
2022	328	1,160	$1,718,888
2023	432	1,669	$2,932,555
2024	516	2,043	$3,937,217

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	15	$576
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	395	771	$94
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	375	675	$13
80053	Blood test, comprehensive group of blood chemicals	339	583	$10
36415	Insertion of needle into vein for collection of blood sample	395	776	$9
86140	Measurement c-reactive protein for detection of infection or inflammation	266	469	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	96	3,193	$1,016,500
Enbrel Mini	Etanercept	87	2,660	$727,457
Rinvoq	Upadacitinib	65	2,130	$443,539
Cosentyx Sensoready (2 Pens)	Secukinumab	18	756	$212,541
Tymlos	Abaloparatide	50	1,500	$144,416

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	165	$5,408	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	21	$116,190	ABBVIE INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Romy Jove Cabacungan, M.D.?

Tedicare shows public-source Medicare data for Romy Jove Cabacungan, M.D. (NPI 1417190828), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Romy Jove Cabacungan, M.D. have ACO affiliation data?

Romy Jove Cabacungan, M.D. is shown with ACO affiliation data for ABC Network (MSSP, ACO ID A5554).

What billing organization is linked to Romy Jove Cabacungan, M.D.?

Romy Jove Cabacungan, M.D. is linked to ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES P C (billing NPI 1366489254) in the available physician profile data.

Does Romy Jove Cabacungan, M.D. have Open Payments data?

Romy Jove Cabacungan, M.D. has 186 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.